|
|
 |
|
Viewing report
|
|
|
|
Dry Overactive Bladder - A Precursor to Wet Overactive Bladder?
Datamonitor, April 2006, Pages: 50
Dry Overactive Bladder (dry OAB) is considered part of the overactive bladder syndrome. However, unlike wet overactive bladder (or urge urinary incontinence), it is normally only associated with urinary urgency and frequency, and not incontinence. Even so, recent studies suggest that these symptoms bother patients, with unpredictable urges disrupting daily activities and quality of life.
Scope of this title:
- Quantitative treatment data from 365 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
- Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and treatment strategy for dry OAB
- Influences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin and solifenacin
- Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline
Highlights of this title:
Opinion leaders often recognize the impact that urge and frequency symptoms can have on a patient, even in the absence of incontinence episodes. However, prescribing physicians in general do not all accept this readily, leading to under prescribing in this patient group.
For many years the terms urge urinary incontinence (UUI) and dry OAB have been used to describe separate syndromes with similar symptoms differentiated by the occurrence or not of incontinence. In fact is may be more suitable to consider overactive bladder as a continuum.
Although pharmacological therapy is used less frequently in dry OAB than in UUI, the products chosen are similar, based on their activity on urge and frequency via detrusor activity; occasionally a less effective product with lower side effects may be chosen for dry OAB as opposed to a stronger, but less well tolerated product for UUI.
Reasons to order your copy:
- Forecast product sales by understanding key aspects of dry OAB epidemiology, diagnosis and treatment
- Gain a better understanding of the challenges facing current and future players in the dry OAB market
- Identify physicians’ key concerns in dry OAB including unmet needs and the attributes that physicians believe are desirable for future treatments
Customers who bought this item also bought
Management of Urinary Incontinence and Overactive Bladder - A Global Overview
Urinary Incontinence and Overactive Bladder - The Perspective of the Continence Nurse in the US
Urge Urinary Incontinence - Poor Differentiation Limiting New Product Uptake
Kidneys and Genito-Urinary System - Overactive Bladder Drug Pipeline Report
Target Product Profiles 2008: Physician Insights on Key Attributes - Urge Urinary Incontinence
Pipeline and Commercial Insight: Urinary Incontinence - Lifecycle management strategies retain mid-term market growth
Urinary Incontinence: Major Milestones
European Urinary Incontinence Therapeutics Markets
Overactive Bladder Therapy Area Pipeline Report
US market size for urinary incontinence ( UI ) drugs by sales in dollars, by number of prescriptions, and by number of overactive bladder sufferers and urge UI sufferers for 1999 and forecast for 2000 to 2004; also, breakout of sales, percent market
Mixed Urinary Incontinence - An Opportunity for Novel Drug Therapies
Stress Urinary Incontinence - Opinion Divided on Drug Therapy
|
|
|
|
